Caplin Point Laboratories Limited — PPTs, 05-02-2026: Investor Presentation

Caplin Point Laboratories delivered strong performance, with 9M FY26 consolidated total revenue up 11.2% YoY to ₹1,674 Cr and Net Profit (PAT) surging 20.5% YoY to ₹477 Cr. Q3 FY26 also saw robust growth, with total revenue at ₹577 Cr (+9.9% YoY) and PAT at ₹166 Cr (+18.4% YoY). Basic EPS increased by 19.6% to ₹61.98 for 9M FY26. US market revenue grew 25% YoY, contributing 20% to total revenue, while Emerging Markets (Latin America & Africa) accounted for 80%.

The company is strategically expanding in Mexico with new product approvals and a planned manufacturing facility, and showing excellent progress in Chile. It's developing GLP-1 products and leveraging "China 2.0" partnerships to bring US/EU-approved products to emerging markets. For regulated markets, Caplin Steriles (CSL) received its first Suspension Injectable product approval in the US and completed qualifications for Line 6 (Pre-Filled Syringes), with Line 7 (Blow-Fill-Seal) underway. Backward integration is advancing with its first API unit nearing regulatory certifications.

Management highlights sustained strong margins and robust cash generation, with Free Cash Reserves at ₹1,381 Cr. Investments of ₹1,000+ Cr in capacity and technology are ongoing, funded by internal accruals, reinforcing a strategy of compliance through automation and sustainable growth.